DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease.

Author(s): Zhang Y(1), Hu C(2), Hong J(1), Zeng J(2), Lai S(3), Lv A(1), Su Q(4), Dong Y(4), Zhou Z(5), Tang W(5), Zhao J(6), Cui L(6), Zou D(7), Wang D(8), Li H(9), Liu C(10), Wu G(11), Shen J(12), Zhu D(13), Wang W(1), Shen W(1), Ning G(14), Xu G(15).

Affiliation(s): Author information: (1)Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China. (2)Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China. (3)Johns Hopkins School of Medicine, Baltimore, MD. (4)Xinhua Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China. (5)Second Xiangya Hospital of Central South University, Changsha, China. (6)Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. (7)Chang Hai Hospital, Second Military Medical University, Shanghai, China. (8)First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China. (9)Sir Run Run Shaw Hospital, Zhejiang Province, China. (10)Jiangsu Province Hospital, Jiangsu Province, China. (11)Shanghai Tenth People's Hospital of Tongji University, Shanghai, China. (12)Nanfang Hospital, Guangdong Province, China. (13)Nanjin Drum Tower Hospital, Jiangsu Province, China. (14)Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China guangning@medmail.com.cn xugw@dicp.ac.cn. (15)Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China guangning@medmail.com.cn xugw@dicp.ac.cn.

Publication date & source: 2014, Diabetes Care. , 37(10):2804-12

OBJECTIVE: We recently demonstrated a beneficial effect of metformin compared with glipizide in type 2 diabetic patients regarding cardiovascular outcomes for 3-year treatment in the SPREAD-DIMCAD study. However, the potential mechanism for the clinical effects remains unclear. Here, we performed a comprehensive lipidomics study to evaluate the different lipid metabolites in serum samples obtained from participants in this study. RESEARCH DESIGN AND METHODS: Liquid chromatography-quadrupole time of flight-mass spectrometry was used to evaluate the different lipid metabolites in serum samples obtained from the participants (21 patients in glipizide group and 23 patients in metformin group) before and after each year of treatment (at 0 [baseline], 1, 2, and 3 years of study drug administration). RESULTS: A total of 118 serum lipid molecular species was identified and quantified. During treatment, metformin induced a substantially greater change in serum lipid species compared with glipizide, especially at the 2- and 3-year time points (with 2, 11, and 12 lipid species being significantly different between the groups after each year of treatment [1, 2, or 3 years], P < 0.05). Among the significantly changed lipid species, three lipid metabolites were linked to long-term composite cardiovascular events (adjusted P < 0.05). After treatment, triacylglycerols (TAGs) of a relatively higher carbon number showed a clearly increased trend in metformin group compared with the glipizide group, whereas the changes in TAGs with different double bonds were minimal. CONCLUSIONS: Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017